United States Market for Psoriatic Arthritis Pharmacotherapy

  • June 2012
  • -
  • Frost & Sullivan
  • -
  • 92 pages

This research service covers the United States psoriatic arthritis pharmaceuticals market from 2009 to 2017, with 2011 as the base year. The focus of this study is prescription therapeutics prescribed and used as well as the background standard of care. Included in the study are products on the market and products in development as well as patient and revenue forecasts. Market challenges, drivers, and restraints are identified and assessed. The market is segmented by classes of drug: tumor necrosis factor (TNF) inhibitors, non-TNF biologics and novel oral disease-modifying antirheumatic drugs (DMARDs).

Executive Summary
•The market for psoriatic arthritis (PsA) pharmacotherapeutics is currently comprised of a single class: tumor necrosis factor (TNF) inhibitors. Availability of alternative therapies for anti-TNF refractory patients represents a significant unmet need.
•Revenue generated from sales of TNF inhibitors for PsA in the United States was approximately $xxx.x million in 2011 and dominated by Amgen. Revenue for the PsA therapeutic area is expected to increase to approximately $x,xxx.x million in 2017, aided by the addition of several new therapies to the market.
•Novel therapies aimed at alternative targets such as interleukin 12/23 (IL-12/23), interleukin-17 (IL-17), interleukin-6 (IL-6), phosphodiesterase type 4 (PDE4) and janus kinase (JAK) are in active development, with a PDE4 inhibitor and an anti-IL-12/23 closest to approval for PsA.
•Development of therapies for this complex disease and market penetration is hindered by several factors including a perception of PsA as a milder disease compared to rheumatoid arthritis (RA), and incompletely understood pathogenesis.
•Although some therapies such as TNF inhibitors that are effective for the treatment of RA are also effective for PsA, this is not always the case due to differences between the two diseases.
•Accumulating evidence supporting the importance of prompt initiation of effective disease modifying therapy for better long-term outcomes for patients with PsA is driving development of novel therapies aimed at improving symptoms and slowing disease progression.
•Estimates of the prevalence of PsA vary widely, but it is generally considered to occur in approximately xx to xx percent of psoriasis sufferers, or approximately xxx,xxx to x.x million men and women in the United States.
•Diagnostic difficulties are thought to result in unawareness of the condition by many patients and significant under-treatment.

Table Of Contents

TABLE OF CONTENTS

Executive Summary 4
Market Overview 10
Psoriatic Arthritis Pharmacotherapeutics Market -
External Challenges: Drivers and Restraints 20
Forecast and Trends 30
Demand Analysis 41
Market Share and Competitive Analysis 44
TNF Inhibitor Segment Breakdown 54
Non-TNF Biologics Segment Breakdown 65
Novel Oral DMARDs Segment Breakdown 73
The Last Word 81
Appendix 86

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

Multiple Sclerosis (MS) Drugs and Biologics : Technologies and Global Markets

Multiple Sclerosis (MS) Drugs and Biologics : Technologies and Global Markets

  • $ 6 650
  • Industry report
  • June 2014
  • by BCC Research

This BCC Research study offers an overview of the multiple sclerosis (MS) disease-modifying product market, including regulatory issues accompanied by detailed analyses and forecasts by product. Its main ...

Sleep Aids : Technologies and Global Markets

Sleep Aids : Technologies and Global Markets

  • $ 6 650
  • Industry report
  • June 2014
  • by BCC Research

Research on the working of the human brain in relation to sleep is a fairly new area, with many new and novel theories. The discovery of new mechanisms and chemicals in the brain has provided expanding ...

Blood-Brain Barrier Technologies and Global Markets

Blood-Brain Barrier Technologies and Global Markets

  • $ 6 650
  • Industry report
  • July 2014
  • by BCC Research

This BCC Research report analyzes the current status of the global therapeutic market for blood-brain barrier (BBB) technologies, including its growth potential, determines its current market status, examines ...

Bcc Research Bitopertin Forecast

August 2014 $ 5 500

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.